Paul Dickinson PhD

CMC: Preclinical and Clinical
Formulation Development

Paul was Senior Clinical Pharmacology Scientist at AstraZeneca and led the clinical pharmacology program to NDA/MAA for AZD9291/osimertinib, which had been awarded ‘breakthrough therapy’ status by the FDA. Formerly Paul was a Principal Scientist within Pharmaceutical Development (AZ) leading both the global biopharmaceutics network and the Medicines Evaluation science community (USA, SE, UK). He is Director and co-founder of Seda Pharmaceutical Development Services, a company providing pharmaceutical development and clinical pharmacology services and consultancy to the Pharma Industry.

FOLLOW US

  • Twitter
  • LinkedIn Social Icon

Copyright © 2012-2020 Inflection Biosciences, Inc. All Rights Reserved